Compare AbbVie Inc (ABBV) vs Braze Inc (BRZE) Price & Performance

AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.

The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.

Braze (BRZE) trades at $24.40, up 2.48% on the day, with a bullish technical outlook and strong analyst support. Revenue growth accelerated to 30% year-over-year in Q1 2027, though the company remains unprofitable with a net income margin of -15.51%. Recent news highlights AI-driven product enhancements and robust customer engagement demand, contributing to positive sentiment despite recent earnings misses relative to expectations.

The investment case hinges on sustained revenue acceleration and path to profitability, supported by a 96% buy rating from analysts and a $34.78 consensus price target. Key risks include persistent losses, competitive pressures in customer engagement software, and sensitivity to enterprise marketing budgets. Upside potential exists if AI adoption drives further growth and margin improvement.